Pular para o conteúdo principal
Ranking Invest

VCYT - Veracyte, Inc.

Segmento: HealthcareVeracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Análise Ranking Invest

Valuation estimado
$ 1.48 Bi
Valor de Mercado
$ 3.28 Bi
Sobrepreço (AV)+121.4%
IVR
0.45A companhia vale 0,45 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
0.02O valuation alternativo equivale a 2% do valor de mercado da companhia.
MLL
0.02O lucro líquido dos controladores em 16 trimestres equivale a 2% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 1.39 Bi

Dívida Líquida

-$ 299.52 Mi

L4T

$ 114.48 Mi

MM4T

20.34%

Indicadores Básicos

ROE

8.25%

Índices de Previsibilidade

Receita Líquida

B0.03

Lucro

E1.19

Margem

E1.74

Índices de Tendência

Receita Líquida

A11.71

Lucro

A9.17

Margem

A8.94

Índices de Endividamento

DIV/PAT

-0.22

DIV/L4T

-2.62

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.